IMRALDI

Subcutaneous biosimilar medications for patient self-administration

COMMERCIAL BRAND
IMRALDI

ACTIVE PRINCIPLE
ADALIMUMAB

TYPE OF DEVICE
PRE-FILLED PEN

LATEX
DO NOT

TEMPERING TIME
60 -70 minutes

START OF INJECTION
Pressing against the skin

CLICK TO THE START (IN PEN)
Yes

CLICK AT THE END (IN PEN)
Yes

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE